Home > Boards > US Listed > Biotechs > Anavex Life Sciences Corp (AVXL)

Ok, here are my notes from the shareholders

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (10) | Next 10 | Previous | Next
brichnyc Member Profile
 
Followed By 16
Posts 1,854
Boards Moderated 0
Alias Born 02/04/13
160x600 placeholder
Anavex Life Sciences Issued New U.S. Patent for ANAVEX®2-73 Treatment of Neurodevelopmental Disorders including Rett Syndrom... GlobeNewswire Inc. - 1/8/2020 7:00:10 AM
Anavex Life Sciences Reports Fiscal Year 2019 Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 12/16/2019 7:00:10 AM
Anavex Life Sciences to Announce Fiscal 2019 Year End Financial Results on Monday December 16, 2019 GlobeNewswire Inc. - 12/10/2019 7:00:10 AM
Citation Growth Corp. (OTCQX: CGOTF) Weathering the Cannabis Downturn InvestorsHub NewsWire - 12/9/2019 7:23:11 AM
Anavex Life Sciences Presents ANAVEX®2-73 (blarcamesine) Data at 12th Clinical Trials on Alzheimer's Disease (CTAD) 2019 Con... GlobeNewswire Inc. - 12/4/2019 7:00:10 AM
Anavex Life Sciences Receives Rare Pediatric Disease Designation from FDA for ANAVEX®2-73 (blarcamesine) for the Treatment o... GlobeNewswire Inc. - 11/14/2019 7:00:00 AM
Anavex Life Sciences Announces Publication of Foundational Data for ANAVEX®2-73 (blarcamesine) in Rett Syndrome GlobeNewswire Inc. - 11/6/2019 7:00:00 AM
Anavex Life Sciences Announces ATTENTION-AD ANAVEX®2-73 Extension Clinical Study in Early Alzheimer’s Disease GlobeNewswire Inc. - 10/9/2019 7:00:00 AM
Anavex Life Sciences Issued New U.S. Patent for Composition of Matter Covering ANAVEX®2-73 for the Treatment of Alzheimer’... GlobeNewswire Inc. - 10/2/2019 7:00:00 AM
Anavex Life Sciences Presented at the 6th Annual European Rett Syndrome Conference Preliminary Clinical Efficacy Data from th... GlobeNewswire Inc. - 9/27/2019 3:00:00 AM
Anavex Life Sciences to Present at the 2019 Cantor Fitzgerald Global Healthcare Conference GlobeNewswire Inc. - 9/26/2019 7:00:00 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 9/23/2019 6:35:19 AM
Anavex Life Sciences to Present at the Ladenburg Thalmann 2019 Healthcare Conference GlobeNewswire Inc. - 9/18/2019 7:00:00 AM
Post-effective Amendment to Registration Statement (pos Am) Edgar (US Regulatory) - 9/17/2019 5:16:10 PM
CLS Holdings (CLSH) $1.15 Price Target - MASS Approval for Recreational License InvestorsHub NewsWire - 9/17/2019 7:17:00 AM
Withdrawal of Registration Statement (ammendment) (aw) Edgar (US Regulatory) - 9/16/2019 4:17:42 PM
Anavex Life Sciences Announces Preliminary Clinical Efficacy Data of its U.S. Phase 2 Clinical Trial of ANAVEX®2-73 in Patie... GlobeNewswire Inc. - 9/16/2019 7:00:00 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 9/13/2019 5:11:08 PM
Prospectus Filed Pursuant to Rule 424(b)(5) (424b5) Edgar (US Regulatory) - 9/13/2019 5:07:24 PM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 9/13/2019 5:02:44 PM
Anavex Life Sciences to Present at the Janney Healthcare Conference 2019 GlobeNewswire Inc. - 9/5/2019 7:00:00 AM
Anavex Life Sciences Announces Initiation of the EXCELLENCE ANAVEX®2-73-RS-003 Clinical Study in Pediatric Patients with Ret... GlobeNewswire Inc. - 9/4/2019 7:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 8/7/2019 4:07:28 PM
Anavex Life Sciences Reports Fiscal 2019 Third Quarter Financial Results And Provides Clinical Study Updates GlobeNewswire Inc. - 8/7/2019 7:00:00 AM
Anavex Life Sciences to Announce Fiscal 2019 Third Quarter Financial Results on Wednesday, August 7th, 2019 GlobeNewswire Inc. - 8/2/2019 7:00:00 AM
brichnyc   Monday, 04/08/19 09:45:57 AM
Re: brichnyc post# 187976
Post # of 231261 
Ok, here are my notes from the shareholders meeting. As I mentioned earlier, I don't think that I can add much more from the others that already posted. Overall I think it was a very good presentation from Dr. Missling. It was the same presentation that we have seen/heard before but the important part were the questions from the group. This type of questioning we don't get to see very often as many times it is part of a separate breakout session.

Session notes:

- 47M shares outstanding with 100M authorized

- Blank check will be approved ( from sidebar convo with Dr. M.)

- Alz Study 208 weeks most of the patients are still on drug.

- Will look at data next at 208 week mark for the original patients.

- My personal favorite, Major publication will publish data from the Phase 2A trail instead of presenting it at a scientific conf.

- Rett first patient has been dosed.

- Likes the idea of accelerated approval for PDD.

- From sidebar, the stock will stabilize once we have data from PDD and Rett. Only need a few key institutions to buy in to help the cause. I said it would be nice to have about 50% of the shares held by funds and the comment was that is not necessary, just a few key ones. They are in discussions with institutions all the time.

- Since Biogen failure seen increased activity in conversations with potential suiters.

- Extension of the trials are requested by the doctors and patients not built into the trial protocol.

- No need to have FDA / USA arm for Alz trial. Only needed if getting enough patients is an issue.

- Trial much cheaper in Australia vs. US.

- Plenty of product to sell with the $1M manufacturing run. If I remember correctly Dr. M stated they have enough product to handle all of Manhattan.

- There is no magic switch from P2B to a P3. It is one trial. I get the feeling from his answer that they continue to keep a low profile on what they are doing with labeling it a P2b/3. He stated one trial and after this trial they are done.

- From sidebar, blank check will only be used for an unwarranted acquisition. It should be enough just to have it to scare away any aggressive suiters who are looking to steal the company.

- Biogen MTA is over and no further testing going on.

If anyone else remembers differently please correct me.

Thanks everyone for their notes as well. Keep up the good info.

Public Reply | Private Reply | Keep | Last ReadPost New MsgReplies (10) | Next 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist